Successful discontinuation rate · participants with depressive or anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · participants with depressive or anxiety disorders
It is very uncertain whether discontinuation by "tapering" changes relapse (as defined by study authors) (HR) compared with continuation (or usual care) (very low certainty).
1 finding from 1 review
Withdrawal symptoms · participants with depressive or anxiety disorders
1 finding from 1 review
Adverse events · participants with depressive or anxiety disorders
It is very uncertain whether discontinuation by "tapering" changes adverse events compared with continuation (or usual care) (very low certainty).
1 finding from 1 review
Depressive symptoms · participants with depressive or anxiety disorders
1 finding from 1 review
Anxiety · participants with depressive or anxiety disorders
1 finding from 1 review
Quality of life · participants with depressive or anxiety disorders
1 finding from 1 review
Social and occupational functioning · participants with depressive or anxiety disorders
1 finding from 1 review
Disease activity · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Maintenance of clinical remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (high certainty).
1 finding from 1 review
Proportion of participants switched to another biologic due to loss of response · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants switched to another biologic due to loss… compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Proportion of participants with minimal radiographic progression · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF disease activity–guided dose tapering showed no clear difference in proportion of participants with minimal radiographic progression compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Function · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found